Review
Version 1
Preserved in Portico This version is not peer-reviewed
A Journey To Reach Ovary Using Next-Generation Technologies
Version 1
: Received: 4 October 2023 / Approved: 6 October 2023 / Online: 6 October 2023 (12:24:42 CEST)
A peer-reviewed article of this Preprint also exists.
Nguyen, T.T.A.; Demeestere, I. A Journey to Reach the Ovary Using Next-Generation Technologies. Int. J. Mol. Sci. 2023, 24, 16593. Nguyen, T.T.A.; Demeestere, I. A Journey to Reach the Ovary Using Next-Generation Technologies. Int. J. Mol. Sci. 2023, 24, 16593.
Abstract
Although effective in term of chance of future live birth, the current methods for fertility preservation such as oocytes, embryo or ovarian tissue cryopreservation cannot be offered to all cancer patients and in all clinical contexts. Expanding options for fertility preservation is crucial to address the need to encompass all situations. One emerging strategy is pharmacoprotection, which is non-invasive and has the potential to fill existing gaps in fertility preservation. Besides the identification of the most efficient therapeutic agent itself, the potential off-target effect re-mains one of the main limitation of this strategy for clinical application, particularly when healthy ovarian tissue is targeted. This review focuses on the advances in pharmacoprotective approaches and the challenge of targeting the ovaries to deliver these agents. The unique properties of gold nanoparticles (AuNPs) make them an attractive candidate for this purpose. We discuss how AuNPs meet many of the requirements for an ideal drug delivery system, as well as the existing limitations that have hindering the progression of AuNPs research into more clinical trials. Additionally, the review highlights microRNA (miRNA) therapy as a next-generation approach to address the issues of fertility preservation and discusses the obstacles that currently impede its clinical availability.
Keywords
gold nanoparticles; microRNA therapies; ovary; fertility preservation
Subject
Medicine and Pharmacology, Reproductive Medicine
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
